Atlas Trials

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Clinical trial NCT03373305 · WITHDRAWN

Trial details

NCT number
NCT03373305
Sponsor
City of Hope Medical Center
Status
WITHDRAWN
Phase
Phase 1
Study type
INTERVENTIONAL
CD30-Positive Neoplastic Cells PresentFolliculotropic Mycosis FungoidesRecurrent Mycosis FungoidesRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Mycosis FungoidesRefractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaSezary Syndrome
Start date
2019-03-01
Primary completion
2019-04-26
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.